EL7.AI
StocksMedium•17 November 2026•
4 min read

SELLAS Reports 41% Reduction in Risk of Death in Acute Myeloid Leukemia Vaccine Trial

Key Facts

1SELLAS said GPS reduced the risk of death by 41% compared with best available therapy.
2Median overall survival was 24.0 months with GPS versus 14.7 months with best available therapy.
3The company reported a hazard ratio of 0.59 and a two-sided p-value of 0.035 for the overall survival result.
4SELLAS plans to prepare a biologics license application in the first half of 2027.

SELLAS Life Sciences announced on November 17 that its Phase 3 REGAL trial met its primary overall survival endpoint, saying its investigational vaccine GPS was associated with a relative 41% reduction in the risk of death compared with best available therapy. Median overall survival was 24.0 months among patients who received GPS, versus 14.7 months in the comparator group. The company said the difference in overall survival was statistically significant, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. The study involves patients with acute myeloid leukemia who achieved complete remission after second-line salvage therapy. The result is the main focus of the data the company announced that day, while it said it is continuing to complete other analyses before presenting the details at a medical conference and publishing them in a peer-reviewed journal.

SELLAS said the trial enrolled 126 patients and randomized them 1:1 between GPS and best available therapy selected by investigators. The comparison included GPS alone versus treatment options determined by investigators, according to the study design described by the company. The trial reached its prespecified threshold of 80 deaths on October 28, triggering the final analysis. The company then said on November 12 that it expected to announce topline results for the primary endpoint during the same month, following database lock, information review and statistical analysis. The November 17 announcement came within the timeline the company had cited before the results were released. Overall survival was the primary endpoint that REGAL reported meeting.

On safety, the company described GPS as generally well tolerated and said treatment-related adverse events were mostly mild to moderate. It added that the most common of those events was injection-site reactions, and that it had reported no new safety signals. This information remains part of the results SELLAS included in its statement about the trial. The comprehensive statistical assessment of secondary endpoints and additional prespecified analyses, the company said, is still ongoing. It said the details would later be presented at a major medical conference and submitted for publication in a peer-reviewed journal. That work includes completing analyses under the statistical plan and study protocol.

SELLAS linked the results to subsequent development and regulatory steps, saying it plans to meet with the U.S. Food and Drug Administration to discuss an accelerated submission strategy. It added that it is working to prepare a biologics license application for the GPS vaccine in the first half of 2027. Those steps remain tied to the regulatory review process the company said it intends to discuss with the agency. In another AML treatment program, the company reported on November 12 that 40 patients had been enrolled in the Phase 2 SLS009 trial for newly diagnosed patients. It said the study is targeting 80 patients, and enrollment and dosing are ongoing. At the time, the company expected topline data in the fourth quarter of 2026.

The cash position reported at the end of September provides context for the company’s resources as it continues its clinical programs: SELLAS said it had $134.7 million in cash and cash equivalents on September 30, 2026. The company did not directly link that balance in the information presented here to the cost of submitting or funding the regulatory application. In the stock market, SLS shares closed at $7.47 on November 16, the session before the REGAL results announcement. That price provides a time reference for the stock’s performance before the news and does not include trading data after the announcement. The next step announced by the company is to complete the analyses and present their details at a medical conference, alongside preparations for the targeted license application in the first half of 2027.

Open on chart